Except for abemaciclib, which can be used as monotherapy in refractory ER+/Her2- breast cancers [186], ribociclib and palbociclib are currently used in combination with aromatase inhibitors, or with fulvestrant for ER+ luminal breast cancers [182,187]. Here, CYP19A1 is linked to breast carcinoma.